You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The partners will leverage MedGenome's database of genetic variants in South Asians to identify and analyze genes and variants associated with Parkinson's disease.
The software tool, currently in development, is set to be introduced next year and could also find application in other indications such as cancer.
RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.
The effort aims to screen for SARS-CoV-2 in the San Diego community and study the virus' genome to better understand how it is transmitted.
The researchers presented their findings during the European Society of Human Genetics meeting, which was webcast this week.
The company and the Harvard TH Chan School of Public Health will study the use of microbial biomarkers to identify precancerous adenomas and carcinomas in the colon.
Seven Bridges will help build a computational infrastructure to harmonize data from Zero Childhood Cancer with datasets from other research projects.
Backed by BARDA, Merck and Institute for Systems Biology are studying multiomic data to understand infection pathways and find biomarkers for symptom risk.
The Cold Spring Harbor Laboratory spinout will build predictive models for lung cancer progression and risk using its SpliceCore software platform.
As part of the deal, Applied DNA will permanently place robotic and diagnostic equipment at the hospital to enable validation of the test.
AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.
Time magazine looks into how liquid biopsies are changing cancer care.
According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.